Download the full report (112 p.) - KCE

More documents

Recommendations

Info

94 Interventions in Alzheimer’s Disease KCE Reports 111 83. Ballard C, Waite J, Birks J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 84. 2006(1):CD003476. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42(1):32-8. 85. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227. 86. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608. 87. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a metaanalysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22(5):475-84. 88. Clegg A, Bryant J, Nicholson T, McIntyre L, De BS, Gerard K, et al. Clinical and costeffectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review. Systematic review. The National Coordinating Centre for Health Technology Assessment (NCCHTA) on behalf of Southampton Health Technology Assessments Centre(SHTAC) Southampton.; 2001. Available from: 89. http://www.hta.ac.uk/execsumm/summ501.htm Shukla VK, Otten N. Drug treatments for Alzheimer's disease. III. A review of pharmacoeconomic evaluations. Systematic review. Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2000. Technology Report Issue 11 Available from: https://www.ccohta.ca/ 90. Knowles J. Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes. Core Evidence. 2006;1(3):195-219. 91. Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.[see comment]. Eur J Health Econ. 2006;7(2):137-44. 92. Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries. Drugs & Aging. 2004;21(10):677-86. 93. Fagnani F, Lafuma A, Pechevis M, Rigaud AS, Traykov L, Seux ML, et al. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dementia & Geriatric Cognitive Disorders. 2004;17(1-2):5-13. 94. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease.[see comment]. Neurology. 95. 2004;63(4):644-50. Francois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease: A Markov model in Finland. Clinical Drug Investigation. 2004;24(7):373-84. 96. Fuh JL, Wang SJ. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. International Journal of Geriatric Psychiatry. 2008;23(1):73-8. 97. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52(8):519-26. 98. Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.[see comment]. Pharmacoeconomics. 2005;23(12):1271-82. 99. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs & Aging. 2004;21(9):607-20. 100. Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother. 2005;3(2):77-86. 101. Martikainen J, Valtonen H, Pirttila T. Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients. Eur J Health Econ. 2004;5(2):136-42.
KCE Reports 111 Interventions in Alzheimer’s Disease 95 102. Teipel SJ, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M. Long-term costeffectiveness of donepezil for the treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2007;257(6):330-6. 103. Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin. 2007;23(5):1187-97. 104. Charlesworth G, Shepstone L, Wilson E, Thalanany M, Mugford M, Poland F. Does befriending by trained lay workers improve psychological well-being and quality of life for carers of people with dementia, and at what cost? A randomised controlled trial. Health Technol Assess. 2008;12(4):iii. 105. Knapp M, Thorgrimsen L, Patel A, Spector A, Hallam A, Woods B, et al. Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis. British Journal of Psychiatry. 2006;188:574-80. 106. Cohen JT, Neumann PJ. Decision analytic models for Alzheimer's disease: State of the art and future directions. Alzheimer's and Dementia. 2008;4(3):212-22. 107. Green C. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics. 2007;25(9):735-50. 108. Kirby J, Green C, Loveman E, Clegg A, Picot J, Takeda A, et al. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease. Drugs Aging. 2006;23(3):227-40. 109. Oremus M. Systematic review of economic evaluations of Alzheimer's disease medications. Expert Review of Pharmacoeconomics and Outcomes Research. 2008;8(3):273-89. 110. Wimo A. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations. Drugs & Aging. 2004;21(5):279-95. 111. Wimo A. Clinical and economic outcomes--friend or foe? Int Psychogeriatr. 2007;19(3):497- 507. 112. Wimo A, Norlund A. Cost-effectiveness of treatments for Alzheimer's dementia. Expert Review of Pharmacoeconomics and Outcomes Research. 2007;7(1):83-90. 113. Wimo A, Norlund A. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Cost-effectiveness studies. Alzheimer's and Dementia. 2007;3(3):157-61. 114. Caro JJ, Getsios D, Migliaccio-Walle K, Raggio G, Ward A, Group AS. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology. 2001;57(6):964-71. 115. Fuh J-L, Pwu R-F, Wang S-J, Chen Y-H. Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population. Int J Geriatr Psychiatry. 2004;19(3):266-70. 116. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 1999;52(6):1138-45. 117. Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making. 2000;20(4):413-22. 118. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37(1):27-32. 119. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry. 1998;13(7):445-53. 120. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebocontrolled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50(1):136-45. 121. Wimo A, Mattsson B, Krakau I, Eriksson T, Nelvig A. Cost-effectiveness analysis of day care for patients with dementia disorders. Health Econ. 1994;3(6):395-404. 122. Wimo A, Wallin JO, Lundgren K, Ronnback E, Asplund K, Mattsson B, et al. Impact of day care on dementia patients--costs, well-being and relatives' views. Fam Pract. 1990;7(4):279-87.
Page 1 and 2:
Pharmaceutical and nonpharmaceutica
Page 3 and 4:
Pharmaceutical and nonpharmaceutica
Page 5 and 6:
KCE reports 111C Interventions in A
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
KCE Reports 111 Interventions in Al
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56: KCE Reports 111 Interventions in Al
Page 105: KCE Reports 111 Interventions in Al
Page 109 and 110: This page is left intentionally bla
Page 111: KCE reports 33 Effects and costs of
show all

Download the full report (112 p.) - KCE

Create successful ePaper yourself

Delete template?

Save as template?